DRIO DarioHealth Corp.

DarioHealth Corp.

Medical/Dental Instruments

Health Care

DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario Tools, which are devices that integrate with applications on a user's smartphone; DarioEngage, a population health management platform; and the Dario Loop, an AI-driven journey engine. It also sells device-specific disposables test strip cartridges, lancets, and Dario Blood Glucose Monitoring System; and Dario Smart Diabetes Management Solution, which includes tools to help diabetic patients manage their disease. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was founded in 2011 and is based in New York, New York.

IPO Year:

Exchange: NASDAQ

Website: mydario.com

Recent Analyst Ratings for DarioHealth Corp.

Date	Price Target	Rating	Analyst
1/29/2025	$2.00 → $1.00	Buy → Hold	TD Cowen
5/13/2022	$8.75	Neutral → Buy	Alliance Global Partners
1/26/2022	$28.00 → $25.00	Buy	Aegis Capital
8/19/2021	$35.00 → $28.00	Buy	Aegis Capital

See more ratings

DarioHealth Corp.

Recent Analyst Ratings for DarioHealth Corp.

DarioHealth Corp. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Franco-Yehuda Chen was granted 500,000 shares (SEC Form 4)

SEC Form 3 filed by new insider Franco-Yehuda Chen

New insider Leisure Lawrence B. claimed ownership of 258,000 shares (SEC Form 3)

Director Kaplan Jon H. was granted 30,000 shares, increasing direct ownership by 37% to 111,574 units (SEC Form 4)

SEC Form 4 filed by Director Stern Adam K

Chief Commercial Officer Nelson Steven Charles bought $4,546 worth of shares (5,000 units at $0.91), increasing direct ownership by 10% to 55,000 units (SEC Form 4)

Chief Commercial Officer Nelson Steven Charles bought $8,244 worth of shares (10,000 units at $0.82), increasing direct ownership by 25% to 50,000 units (SEC Form 4)

Chief Commercial Officer Nelson Steven Charles bought $12,292 worth of shares (15,000 units at $0.82), increasing direct ownership by 60% to 40,000 units (SEC Form 4)

Chief Executive Officer Raphael Erez bought $4,400 worth of shares (5,000 units at $0.88), increasing direct ownership by 0.26% to 1,937,059 units (SEC Form 4)

Chief Commercial Officer Nelson Steven Charles bought $14,147 worth of shares (15,000 units at $0.94), increasing direct ownership by 150% to 25,000 units (SEC Form 4)